AGM
ORMP icon

Alpine Global Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Alpine Global Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-43,013
Closed -$614K – 640
2021
Q4 		$614K Buy
+43,013
New +$899K 0.09% 357

Other funds holding ORMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

Alpine Global Management's ORMP Position: Q1 2022 in Review

Alpine Global Management sold out of Oramed Pharmaceuticals (ORMP) in Q1 2022, closing a stake of 43,013 shares — an estimated $614K sold.

Alpine Global Management first reported a position in ORMP in Q4 2021 and held it in 1 quarter. The position peaked at $614K in Q4 2021. 103 funds tracked by Wall St. Rank hold ORMP as of Q1 2022.

  • Alpine Global Management reported no remaining Oramed Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Alpine Global Management sold 43,013 Oramed Pharmaceuticals shares in Q1 2022, an estimated $614K.
  • Alpine Global Management first reported a position in Oramed Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Alpine Global Management's Oramed Pharmaceuticals position peaked at $614K in Q4 2021.
  • 103 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2022.

Based on Alpine Global Management's 13F filing for Q1 2022, filed 13 May 2022.